Review: cellular senescence in diabetic cardiomyopathy and senescence-targeting strategies
This review links cellular senescence in the diabetic heart to mitochondrial dysfunction, inflammation and remodeling, notes distinct patterns in type 1 and type 2 diabetes, and describes senescence-targeting strategies tested in preclinical and emerging clinical studies. [1]
Automatic summary · not editorially reviewed
The key findings
The review describes diabetic cardiomyopathy as a distinct disorder developing independently of other overt cardiovascular diseases, with cellular senescence proposed as a central mechanism linking metabolic stress to mitochondrial dysfunction, inflammation and adverse remodeling. [1]
In the diabetic heart, senescence is described as sustained cell-cycle arrest, impaired mitochondrial function and a proinflammatory senescence-associated secretory phenotype, with signaling pathways including p53, FOXO1–ANGPTL4 and microRNA-dependent mechanisms implicated. [1]
Senolytics, metabolic modulators, mitochondrial protectants and epigenetic regulators are said to have shown potential in preclinical and emerging clinical studies, and type 1 and type 2 diabetes are noted to show distinct senescence patterns. [1]
The source at a glance
- Study type / format
- Review article (abstract only)
- Population / context
- People with diabetic cardiomyopathy, as discussed in a review of cellular senescence mechanisms
- Summary based on
- Study abstract
- Original publication
- July 28, 2026
Senescence as a proposed central mechanism in the diabetic heart
The review describes diabetic cardiomyopathy as a distinct cardiac disorder with diabetes-associated structural and functional myocardial abnormalities that develops independently of other overt cardiovascular diseases. It states that growing evidence suggests cellular senescence is a central mechanism linking metabolic stress to mitochondrial dysfunction, chronic inflammation and adverse cardiac remodeling. In the diabetic heart, senescence is said to appear as sustained cell-cycle arrest, impaired mitochondrial function and a proinflammatory senescence-associated secretory phenotype (SASP). Together, the review says, these features drive detrimental structural and functional remodeling.
Supporting source [1]
Signaling, epigenetics and immune crosstalk described in the review
Mechanistically, the review ties the process to defective mitochondrial quality control influenced by regulators such as Sirtuin 3 (SIRT3) and ATP synthase O subunit (ATP5O). It also describes aberrant activation of signaling pathways, including p53, FOXO1–Angiopoietin-like 4 (ANGPTL4) and various microRNA-dependent mechanisms, as driving senescence in both cardiomyocytes and cardiac progenitor cells under diabetic conditions. Epigenetic remodeling and RNA methylation are said to further shape the process by influencing transcriptional regulation and protein homeostasis. Immunoinflammatory crosstalk, particularly macrophage polarization and persistent SASP-mediated inflammation, is described as worsening myocardial fibrosis and dysfunction. The review notes that type 1 and type 2 diabetes show distinct patterns of senescence burden, mitochondrial impairment and cardiac phenotypes.
Supporting source [1]
Senescence-targeting strategies: preclinical and emerging clinical evidence
The review states that promising therapeutic strategies targeting senescence-associated pathways have shown potential in preclinical and emerging clinical studies. These include senolytics, metabolic modulators, mitochondrial protectants and epigenetic regulators. The review integrates current insights into the interplay among metabolic stress, mitochondrial injury and cellular senescence in diabetic cardiomyopathy and highlights directions for mechanism-based interventions aimed at countering diabetic cardiac remodeling. It does not report specific effect sizes, trial names or outcome results for these strategies.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no study design details, sample sizes, effect sizes or outcome results for the cited preclinical and clinical work, and the therapeutic strategies are described only as showing potential.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ye T, Yang D, Chang X, Wu D, Lei Y, Mu C, Zhao Y, Xu S. · europepmc.org · July 28, 2026